Benefits
Shifts gut fatty acids toward butyrate
In a 12-week study of adults with features of metabolic syndrome, daily supplementation shifted the mix of short-chain fatty acids the gut bacteria produce toward more butyrate, the preferred fuel for the cells lining the colon.
Supports a calmer gut environment
In the same study, the flavonoid extract was associated with a trend toward lower fecal calprotectin, a marker of gut inflammation, although this change did not reach statistical significance.
Prebiotic-like microbiome support
Rather than being fully absorbed, the citrus flavonoids reach the colon and are used by gut bacteria. In laboratory colon-model studies the extract nourished beneficial, short-chain-fatty-acid-producing species.
Mechanism of action
Converted by gut bacteria into active metabolites
Flavonoids such as hesperidin pass largely undigested into the colon, where resident bacteria cleave and transform them into smaller phenolic metabolites that are more readily absorbed and biologically active.
Fuels short-chain fatty acid production
By serving as a substrate for colonic fermentation, the flavonoids shift bacterial output toward short-chain fatty acids such as butyrate and acetate, which nourish the gut lining and help regulate the local immune environment.
Flavonoid antioxidant and anti-inflammatory activity
Hesperidin, naringin, and their microbial metabolites show antioxidant and anti-inflammatory activity in laboratory studies, which may contribute to the lower gut-inflammation marker seen in the human data.
Clinical trials
Randomised, double-blind, placebo-controlled trial of 500 mg/day citrus flavonoid extract for 12 weeks, paired with in vitro TIM-2 colon-model fermentation of the subjects' fecal samples (Maurer Sost M, Stevens Y, Salden B, Troost F, Masclee A, Venema K 2023, Foods 12(18):3413, PMID 37761122).
Adults with features of metabolic syndrome (overweight with low-grade gut inflammation); the manufacturer reports about 50 participants.
Twelve weeks of daily supplementation produced a significant shift in the short-chain fatty acid profile toward butyrate (p=0.022) versus placebo, plus a trend toward lower fecal calprotectin, a gut-inflammation marker, that did not reach significance (p=0.058). A single manufacturer-associated trial measuring gut biomarkers rather than clinical disease endpoints.
Fermentation of the citrus extract in the validated TIM-2 colon model seeded with fecal microbiota from healthy donors, at doses equivalent to 250 and 350 mg/day (Sost MM, Ahles S, Verhoeven J, Verbruggen S, Stevens Y, Venema K 2021, Nutrients 13(11):3915, PMID 34836169).
Laboratory colon model seeded with fecal microbiota from healthy human volunteers (not a human trial).
The extract dose-dependently increased beneficial bacteria such as Roseburia and raised cumulative short-chain fatty acid production; in this particular model the SCFA shift favored acetate rather than butyrate. Mechanistic in vitro support for a prebiotic-like effect, not a clinical outcome.